Dr. SHOU Jiawei graduated from the seven-year program at Zhejiang University School of Medicine in 2007, and later obtained a Ph.D. in oncology from the same institution. His main focus during the doctoral studies was the research on the resistance mechanisms of targeted drugs for lung cancer, and his clinical focus was on targeted and immunotherapy resistance in lung cancer. In 2019, Dr. Shou went to Mayo Clinic in the United States to study cancer genetics. After returning to China, he initiated projects on cancer genetic gene monitoring and clinical research on cancer vaccines. Dr. Shou has led or participated in multiple national and provincial medical research projects and has published over ten professional papers.

Youth member of the Tumor Targeted Therapy Professional Committee of the Chinese Anti-Cancer Association

Member of the Tumor Molecular Targeted Therapy Professional Committee of the Chinese Society of Biomedical Engineering

Member of the Biliary Tumor Expert Committee of the Chinese Society of Clinical Oncology

Secretary of the Zhejiang Cancer Targeted Technology Guidance Center